


This listing of claims will replace all prior versions, and listings, of claims in the application.


Listing of Claims

1. (*currently amended*) A compound of Formula I:



wherein

Q is



R^1 , R^2 and R^3 are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, alkanesulfonyl of 1 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms;

X and Y are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamide of 2 to 6 carbon

~~atoms, alkanesulfonyl of 1 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms, or X and Y, taken together, form -N=C(R⁴)-C(R⁵)=N-, -N=C(R⁴)-C(R⁶)=CH-, -N=C(R⁴)-N=CH-, N=C(R⁴)-O-, NH-C(R⁷)=N or NH-C(R⁸)=CH-~~

R⁴ and R⁵ are, independently, hydrogen, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;

R⁶ is hydrogen or alkyl of 1 to 6 carbon atoms;

~~R⁷ is hydrogen, halo, trifluoromethyl, pentafluoroethyl, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;~~

~~R⁸ is hydrogen, halo, trifluoromethyl, pentafluoroethyl, or alkyl of 1 to 6 carbon atoms;~~

Z is O, S, or NR⁹, in which R⁹ is hydrogen or alkyl of 1 to 6 carbon atoms;

n is an integer 0, 1, or 2;

m is an integer from 1 to ~~4~~ 2, provided that m + n ≤ 4 and that when m = n = 2, and Q is b then X and Y are not NH-C(R⁸)=CH-; and

p is an integer from 1 to ~~3~~ 2, provided that p + n is 2 or 3;

or a pharmaceutically acceptable salt thereof.

2-3. (*cancelled*)

4. (*original*) A compound according to claim 1, wherein Z is NR⁹ or a pharmaceutically acceptable salt thereof.

5. (*currently amended*) A compound according to claim 1, wherein n is ~~0 or~~ 1 or a pharmaceutically acceptable salt thereof.

6. (*currently amended*) A compound according to claim 1, wherein m is ~~1 to 3~~ 1 or a pharmaceutically acceptable salt thereof.

7. (*currently amended*) A compound according to claim 1, wherein p is 1 ~~or 2~~ or a pharmaceutically acceptable salt thereof.

8. (*original*) A compound according to claim 1, wherein R¹ is hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.

9. (*original*) A compound according to claim 1, wherein R² and R³ are independently selected from hydrogen, hydroxy, halo, cyano, carboxamido, alkyl of 1 to 6 carbon atoms, or alkoxy of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.

10. (*original*) A compound according to claim 1, wherein R⁴ and R⁵ are independently hydrogen, amino or alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.

11. (*cancelled*)

12. (*currently amended*) A compound according to claim 1, wherein R⁶ is hydrogen or alkyl of 1 to 3 carbon atoms, Z is NR⁹ in which R⁹ is hydrogen or alkyl of 1 to 3 carbon atoms, ~~n is 0 or 1, m is 1 to 3 and p is 1 or 2~~ or a pharmaceutically acceptable salt thereof.

13. (*cancelled*)

14. (*original*) A compound according to claim 1, wherein said compound is 2-[3-(5-fluoro-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

15-16. (*cancelled*)

17. (*original*) A compound according to claim 1, wherein said compound is 2-[3-(1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

18. (*original*) A compound according to claim 1, wherein said compound is 2-[3-(5-fluoro-1-methyl-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

19-24. (*cancelled*)

25. (*original*) A compound according to claim 1, wherein said compound is 8-Methyl-2-[3-(5-methyl-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

26. (*original*) A compound according to claim 1, wherein said compound is the S enantiomer at the 2-aminomethyl-2,3-dihydro-1,4-benzodioxan moiety, substantially free of the R enantiomer of said compound.

27-29. (*cancelled*)

30. (*original*) A pharmaceutical composition, comprising:
an effective amount of a compound according to claim 1; and
a pharmaceutically acceptable carrier or excipient.

31. (*new*) A compound selected from the group consisting of:
2-[3-(5-fluoro-1H-indol-3-ylmethyl)-piperidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline;
2-[3-(6-fluoro-1H-indol-3-ylmethyl)-piperidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline;

2-($\{4-[6\text{-fluoro-}1\text{H-indol-}1\text{-yl)methyl]piperidin-1\text{-yl}\})$ -8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline;

2-($\{4-[6\text{-fluoro-}1\text{H-indol-}1\text{-yl)ethyl]piperidin-1\text{-yl}\})$ -8-ethyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline;

1-[$(1-\{[8\text{-methyl-}2,3\text{-dihydro[1,4]-dioxino[2,3-f]quinolin-2-yl]methyl\})$ piperidin-4-yl]-1H-indole-6-carbonitrile;

2-[3-(6-fluoro-indol-1-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline;

2-{3-[2-(6-fluoro-indol-1-yl)-ethyl]-azetidin-1-ylmethyl}-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline;

1-{2-[1-(8-methyl-2,3-dihydro-[1,4]-dioxino[2,3-f]quinolin-2-ylmethyl)-azetinin-3-yl]-ethyl}-1H-indole-6-carbonitrile; and

pharmaceutically acceptable salts thereof.